Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 4 2Phase 1/2 2Phase 2/3 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Melanoma 10Neoplasm Metastasis 3Neoplasms 2Glioma 2Skin Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neurofibroma, Plexiform 1Neuroblastoma 1Melanoma, Cutaneous Malignant 1Histiocytosis, Langerhans-Cell 1Hematologic Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Adenocarcinoma 1

Interventions

Temozolomide 26Radiotherapy 10Bevacizumab 10Carboplatin 6Irinotecan 5pembrolizumab 4Radiation 4Nivolumab 4IL13-PE38 4temsirolimus 3Surgical Procedures, Operative 3Magnetic Resonance Spectroscopy 3Immunotherapy, Adoptive 3Erlotinib Hydrochloride 3Aminolevulinic Acid 3trametinib 2olaparib 2lutetium Lu 177 dotatate 2fludarabine 2dabrafenib 2cemiplimab 2abemaciclib 2Vorinostat 2Transurethral Resection of Bladder 2Sirolimus 2Radiotherapy, Intensity-Modulated 2Radiosurgery 2Imatinib Mesylate 2Flucytosine 2Cyclophosphamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Glioma × dabrafenib × Clear all
NCT04201457 2026-02-03

A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration

Pediatric Brain Tumor Consortium

Phase 1/2 Active not recruiting
57 enrolled
CNS

Glioma

NCT06712875 2025-05-29

MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas

Ann & Robert H Lurie Children's Hospital of Chicago

Phase 1/2 Recruiting
27 enrolled
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡